Proteomics of Breast Cancer

Progresses in screening, early diagnosis, prediction of aggressiveness and of therapeutic response or toxicity, and identification of new targets for therapeutic will improve survival of breast cancer. These progresses will likely be accelerated by the new proteomic techniques. In this review, we describe the different techniques currently applied to clinical samples of breast cancer and the most important results obtained with the two most popular proteomic approaches in translational research (tissue microarrays and SELDI-TOF).

[1]  Axel Hoos,et al.  Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations , 2001, Laboratory Investigation.

[2]  P. O’Farrell.  High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.

[3]  K. Sandelin,et al.  Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment , 2004, Molecular & Cellular Proteomics.

[4]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[5]  Brian B Haab,et al.  Antibody Arrays in Cancer Research , 2005, Molecular & Cellular Proteomics.

[6]  Lisa H. Cazares,et al.  Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer , 2004, Annals of Surgical Oncology.

[7]  Yu Shyr,et al.  Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.

[8]  C. Perou,et al.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.

[9]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[10]  Joanna S Morris,et al.  Annexin A8 Is Up-Regulated During Mouse Mammary Gland Involution and Predicts Poor Survival in Breast Cancer , 2005, Clinical Cancer Research.

[11]  M. Salto‐Tellez,et al.  Tissue microarray study for classification of breast tumors. , 2003, Life sciences.

[12]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[13]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[14]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[15]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Rijn,et al.  Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray , 2003, Virchows Archiv.

[17]  G. Sauter,et al.  Prognostic relevance of MAGE‐A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study , 2002, International journal of cancer.

[18]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[19]  P. Sorger,et al.  Profiling receptor tyrosine kinase activation by using Ab microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Carlos Caldas,et al.  Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[21]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[22]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Roy A Jensen,et al.  Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. , 2004, The American journal of pathology.

[25]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[26]  Stephen Alexander,et al.  Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid , 2004, Clinical Cancer Research.

[27]  O. Kallioniemi,et al.  EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers , 2005, Clinical Cancer Research.

[28]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Hirano,et al.  Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. , 1996, British Journal of Cancer.

[30]  Michael Peacock,et al.  Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma , 2004, Clinical Cancer Research.

[31]  M. Bittner,et al.  Data management and analysis for gene expression arrays , 1998, Nature Genetics.

[32]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[33]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[34]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[35]  E. Izbicka,et al.  Fine-needle aspiration in PreservCyt®: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF , 2004, Modern Pathology.

[36]  E. Devilard,et al.  Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. , 2002, Human molecular genetics.

[37]  F. Bertucci,et al.  Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. , 1999, Human molecular genetics.

[38]  L. Liotta,et al.  Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.

[39]  A. Brazma,et al.  Gene expression data analysis. , 2001, FEBS letters.

[40]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[41]  Martin Eisenacher,et al.  Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.

[42]  J. Kononen,et al.  Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[44]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[45]  D. Rimm,et al.  Tissue Microarray Analysis of β-Catenin in Colorectal Cancer Shows Nuclear Phospho-β-catenin Is Associated with a Better Prognosis , 2001 .

[46]  F. Bertucci,et al.  Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters , 2004, Oncogene.

[47]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[48]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[49]  Jeffrey S. Morris,et al.  Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. , 2003, Clinical chemistry.

[50]  Laurence Lodé,et al.  Surface‐enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node‐negative breast cancer tumors , 2006, Proteomics.

[51]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[52]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Speckman,et al.  Proteomic analysis of nipple aspirate fluid using SELDI‐TOF‐MS , 2005, International journal of cancer.

[54]  F. Bertucci,et al.  Gene expression profiling of primary breast carcinomas using arrays of candidate genes. , 2000, Human molecular genetics.

[55]  T. Hirano,et al.  Assessment of homogeneity in polypeptide expression in breast carcinomas shows widely variable expression in highly malignant tumors , 1996, International journal of cancer.

[56]  Stephen Russell,et al.  Proteomics of breast carcinoma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[57]  A. Vlahou,et al.  A novel approach toward development of a rapid blood test for breast cancer. , 2003, Clinical breast cancer.

[58]  A. Frigessi,et al.  Analysis of the humoral immune response to immunoselected phage‐displayed peptides by a microarray‐based method , 2004, Proteomics.

[59]  S. Mendrinos,et al.  Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface‐enhanced laser desorption and ionization‐time of flight mass spectrometry , 2005, Cancer.

[60]  Cornelius Diamond,et al.  A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Daniel Birnbaum,et al.  Identification and validation of an ERBB2 gene expression signature in breast cancers , 2004, Oncogene.

[62]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[63]  J. Giltnane,et al.  Technology Insight: identification of biomarkers with tissue microarray technology , 2004, Nature Clinical Practice Oncology.

[64]  I. Gromova,et al.  Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients , 2005, Molecular & Cellular Proteomics.

[65]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[66]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[67]  J. Xie,et al.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Celis,et al.  Down-regulation of the Tumor Suppressor Protein 14-3-3σ Is a Sporadic Event in Cancer of the Breast , 2005, Molecular & Cellular Proteomics.

[69]  D. Botstein,et al.  Copyright © American Society for Investigative Pathology Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology , 2022 .

[70]  David L Rimm,et al.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. , 2004, The American journal of pathology.

[71]  F. Bertucci,et al.  Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? , 2001, The Lancet. Oncology.

[72]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Kelly K. Hunt,et al.  Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry , 2004, Breast Cancer Research and Treatment.

[74]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[75]  A. Shevchenko,et al.  Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry , 1996, Nature.

[76]  Jiekai Yu,et al.  SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. , 2005, Breast.

[77]  H. Tajiri,et al.  Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. , 2005, Anticancer research.

[78]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[79]  D. Birnbaum,et al.  Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.

[80]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[81]  David E. Misek,et al.  Isoelectric focusing nonporous RP HPLC: a two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry. , 2000, Analytical chemistry.

[82]  Carlos Caldas,et al.  Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index , 2006, Clinical Cancer Research.

[83]  Nasreen S Jessani,et al.  A streamlined platform for high-content functional proteomics of primary human specimens , 2005, Nature Methods.

[84]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[86]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[87]  E. Sauter,et al.  Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer , 2002, British Journal of Cancer.

[88]  H. Stein,et al.  Telomerase as a prognostic marker in breast cancer: high‐throughput tissue microarray analysis of hTERT and hTR , 2002, The Journal of pathology.

[89]  F. Bertucci,et al.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.

[90]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[91]  T. Pawlik,et al.  Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein , 2006, BMC Cancer.

[92]  P. Furmanski,et al.  A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. , 1987, Journal of immunological methods.

[93]  Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions , 2006, Biochemistry (Moscow).

[94]  G. Sauter,et al.  Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. , 2005, Endocrine-related cancer.

[95]  F. Révillion,et al.  Proteomics of breast cancer for marker discovery and signal pathway profiling , 2001, Proteomics.

[96]  M. Tyers,et al.  From genomics to proteomics , 2003, Nature.

[97]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[98]  S. Hecht,et al.  The N-pentenoyl protecting group for aminoacyl-tRNAs. , 2005, Methods.

[99]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[100]  K. Baggerly,et al.  Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma , 2004, Cancer.

[101]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[102]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[103]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[104]  Shiyong Li,et al.  Identification of interleukin‐8 as estrogen receptor‐regulated factor involved in breast cancer invasion and angiogenesis by protein arrays , 2004, International journal of cancer.

[105]  Kevin R Coombes,et al.  Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. , 2004, Surgery.

[106]  T. Hirano,et al.  The development of a cell array and its combination with laser-scanning cytometry allows a high-throughput analysis of nuclear DNA content. , 2000, The American journal of pathology.

[107]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[108]  H. Battifora.  The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[109]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[110]  D L Rimm,et al.  Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[112]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[113]  F. Bertucci,et al.  Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy , 2006, Oncogene.

[114]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[115]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[117]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[118]  David L Rimm,et al.  Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. , 2003, Cancer research.

[119]  G. Sauter,et al.  KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[121]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[122]  Daniel Birnbaum,et al.  Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.

[123]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[124]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[125]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  David L Rimm,et al.  Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer , 2005, Clinical Cancer Research.

[127]  F. Bertucci,et al.  Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer , 2003, International journal of cancer.

[128]  M. Waltham,et al.  Identification of gel‐separated tumor marker proteins by mass spectrometry , 2000, Electrophoresis.

[129]  F. Révillion,et al.  Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells , 2001 .

[130]  Barbara Magi,et al.  Protein expression profiles in human breast ductal carcinoma and histologically normal tissue , 1997, Electrophoresis.

[131]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[132]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[133]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[134]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[135]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[136]  T Hardmeier,et al.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. , 2000, The American journal of pathology.

[137]  T. Kang,et al.  Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons , 2003, Proteomics.

[138]  E. Kubista,et al.  Use of High-Throughput Protein Array for Profiling of Differentially Expressed Proteins in Normal and Malignant Breast Tissue , 2004, Breast Cancer Research and Treatment.

[139]  M J O'Hare,et al.  Linking gene expression patterns to therapeutic groups in breast cancer. , 2000, Cancer research.

[140]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[141]  S. Varnum,et al.  Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. , 2002, Journal of proteome research.

[142]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[143]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.